Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Microbix Biosystems Inc > A second pandemic...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(121)
•••
Post by prophetoffactzon Jun 22, 2023 3:50pm
176 Views
Post# 35509873

A second pandemic...

A second pandemic...There is an acute phase of COVID and it leaves behind long-term damage to those infected that can accumulate with the number of infections. Even assymptomatic and mild cases can cause lasting damage and patients may require monitoring. Policy makers have tried to move on and ignore this; but the bill is now having to be paid. When policy markers take into account the long term costs of this virus on human  health and the health care system they may once again return to the importance of diagnostics and prevention which have been substantially abandoned.

SGriffin_Lab
 
“We know that Covid has caused direct [Covid leading to new cardiovascular disease], indirect [reduced treatment and prevention of cardiovascular disease] and long-term effects [cardiovascular disease and long Covid],” Prof John Greenwood

...When will the UK and other countries start including COVID sequelae in their risk assessments and strategies?
@Sunny_Rae1
When will the "government" address waiting times and ambulance responses? Bloody shambles.

Health bosses warn of heart disease emergency in England

Charity calls for prioritisation of NHS heart care after nearly 100,000 excess deaths since March 2020
Health bosses warn of heart disease emergency in England | Heart disease | The Guardian


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities